This work is licensed under the Creative Commons Attribution 4.0 International License.
Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol 2018; 6: 404–15. doi: 10.1016/s2213-8587(17)30401-1AuernhammerCJSpitzwegCAngeleMKBoeckSGrossmanANöltingSAdvanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategiesLancet Diabetes Endocrinol201864041510.1016/s2213-8587(17)30401-1Open DOISearch in Google Scholar
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3: 1335–42. doi: 10.1001/jamaoncol.2017.0589DasariAShenCHalperinDZhaoBZhouSXuYTrends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United StatesJAMA Oncol2017313354210.1001/jamaoncol.2017.0589Open DOISearch in Google Scholar
Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004; 1014: 13–27. doi: 10.1196/annals.1294.002KlöppelGPerrenAHeitzPUThe gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classificationAnn NY Acad Sci20041014132710.1196/annals.1294.002Open DOISearch in Google Scholar
Briest F, Grabowski P. PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics 2014; 4: 336–65. doi: 10.7150/thno.7851BriestFGrabowskiPPI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsTheranostics201443366510.7150/thno.7851Open DOISearch in Google Scholar
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514–23. doi: 10.1056/NEJMoa1009290YaoJCShahMHItoTBohasCLWolinEMVan CutsemEEverolimus for advanced pancreatic neuroendocrine tumorsN Engl J Med20113645142310.1056/NEJMoa1009290Open DOISearch in Google Scholar
Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 2018; 19: 909–28. doi: 10.1080/14656566.2018.1476492LeeLItoTJensenRTEverolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequenceExpert Opin Pharmacother2018199092810.1080/14656566.2018.1476492Open DOISearch in Google Scholar
Akirov A, Larouche V, Alshehri S, Asa SL, Ezzat S. Treatment options for pancreatic neuroendocrine tumors. Cancers 2019; 11: 828. doi: 10.3390/cancers11060828AkirovALaroucheVAlshehriSAsaSLEzzatSTreatment options for pancreatic neuroendocrine tumorsCancers20191182810.3390/cancers11060828Open DOISearch in Google Scholar
Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, et al. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev 2015; 34: 823–42. doi: 10.1007/s10555-015-9598-5Garcia-CarboneroRGarcia-FigueirasRCarmona-BayonasASevillaITeuleAQuindosMImaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in developmentCancer Metastasis Rev2015348234210.1007/s10555-015-9598-5Open DOISearch in Google Scholar
Choi JI, Imagawa DK, Bhosale P, Bhargava P, Tirkes T, Seery TE, et al. Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib. Clin Mol Hepatol 2014; 20: 218–22. doi: 10.3350/cmh.2014.20.2.218ChoiJIImagawaDKBhosalePBhargavaPTirkesTSeeryTEMagnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenibClin Mol Hepatol2014202182210.3350/cmh.2014.20.2.218Open DOISearch in Google Scholar
Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer 2014; 120: 711–21. doi: 10.1002/cncr.28493KrajewskiKMNishinoMFranchettiYRamaiyaNHVan den AbbeeleADChoueiriTKIntraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteriaCancer20141207112110.1002/cncr.28493Open DOISearch in Google Scholar
Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, Garcia-Carbonero R, Custodio A, Benavent M, et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Br J Cancer 2019; 121: 537–44. doi: 10.1038/s41416-019-0558-7Solis-HernandezMPFernandez Del ValleACarmona-BayonasAGarcia-CarboneroRCustodioABenaventMEvaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)Br J Cancer20191215374410.1038/s41416-019-0558-7Open DOISearch in Google Scholar
Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, Neumann R, Haug AR, Jansen N, et al. Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging 2013; 40: 897–907. doi: 10.1007/s00259-013-2371-5Schmid-TannwaldCSchmid-TannwaldCMMorelliJNNeumannRHaugARJansenNComparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreasEur J Nucl Med Mol Imaging20134089790710.1007/s00259-013-2371-5Open DOISearch in Google Scholar
Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440: 461–75. doi: 10.1007/s00428-002-0609-xPapottiMBongiovanniMVolanteMAllìaELandolfiSHelboeLExpression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysisVirchows Arch20024404617510.1007/s00428-002-0609-xOpen DOISearch in Google Scholar
Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 2010; 35: 321–8. doi: 10.1097/RLU.0b013e3181d6677cVersariACamelliniLCarlinfanteGFrasoldatiANicoliFGrassiEGa-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective studyClin Nucl Med201035321810.1097/RLU.0b013e3181d6677cOpen DOISearch in Google Scholar
Singh S, Poon R, Wong R, Metser U. 68Ga PET Imaging in patients with neuroendocrine tumors: a systematic review and meta-analysis. Clin Nucl Med 2018; 43: 802–10. doi: 10.1097/rlu.0000000000002276SinghSPoonRWongRMetserU68Ga PET Imaging in patients with neuroendocrine tumors: a systematic review and meta-analysisClin Nucl Med2018438021010.1097/rlu.0000000000002276Open DOISearch in Google Scholar
Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 844–60. doi: 10.1016/j.annonc.2020.03.304PavelMÖbergKFalconiMKrenningEPSundinAPerrenAGastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol2020318446010.1016/j.annonc.2020.03.304Open DOISearch in Google Scholar
Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol 2017; 29: 11–6. doi: 10.1016/j.anndiagpath.2017.04.005KimJYHongSMRoJYRecent updates on grading and classification of neuroendocrine tumorsAnn Diagn Pathol20172911610.1016/j.anndiagpath.2017.04.005Open DOISearch in Google Scholar
Yao JC, Pavel M, Lombard-Bohas C, Cutsem EV, Voi M, Brandt U, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, Phase III RADIANT-3 study. J Clin Oncol 2016; 34: 3906–13. doi: 10.1200/jco.2016.68.0702YaoJCPavelMLombard-BohasCCutsemEVVoiMBrandtUEverolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, Phase III RADIANT-3 studyJ Clin Oncol20163439061310.1200/jco.2016.68.0702Open DOISearch in Google Scholar
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387: 968–77. doi: 10.1016/s0140-6736(15)00817-xYaoJCFazioNSinghSBuzzoniRCarnaghiCWolinEEverolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyLancet20163879687710.1016/s0140-6736(15)00817-xOpen DOISearch in Google Scholar
Cherk MH, Kong G, Hicks RJ, Hofman MS. Changes in biodistribution on (68)Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. Cancer Imaging 2018; 18: 3. doi: 10.1186/s40644-018-0136-xCherkMHKongGHicksRJHofmanMSChanges in biodistribution on (68)Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogressionCancer Imaging201818310.1186/s40644-018-0136-xOpen DOISearch in Google Scholar
Weber M, Telli T, Kersting D, Seifert R. Prognostic implications of PET-derived tumor volume and uptake in patients with neuroendocrine tumors. Cancers 2023; 15: 3581. doi: 10.3390/cancers15143581WeberMTelliTKerstingDSeifertRPrognostic implications of PET-derived tumor volume and uptake in patients with neuroendocrine tumorsCancers202315358110.3390/cancers15143581Open DOISearch in Google Scholar
Kratochwil C, Mavriopoulou E, Rath D, Afshar-Oromieh A, Apostolopoulos D, Haufe S, et al. Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy. Q J Nucl Med Mol Imaging 2015; 59: 116–20. PMID: 24382404KratochwilCMavriopoulouERathDAfshar-OromiehAApostolopoulosDHaufeSComparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomyQ J Nucl Med Mol Imaging20155911620PMID:24382404Search in Google Scholar
Sarikaya I, Sarikaya A, Alnafisi N, Alenezi S. Significance of splenic uptake on somatostatin receptor imaging studies. Nucl Med Rev Cent East Eur 2018; 21: 66–70. doi: 10.5603/NMR.a2018.0012SarikayaISarikayaAAlnafisiNAleneziSSignificance of splenic uptake on somatostatin receptor imaging studiesNucl Med Rev Cent East Eur201821667010.5603/NMR.a2018.0012Open DOISearch in Google Scholar
Schieren G, Bölke E, Scherer A, Raffel A, Gerber PA, Kröpil P, et al. Severe everolimus-induced steatohepatis: a case report. Eur J Med Res 2013; 18: 22. doi: 10.1186/2047-783x-18-22SchierenGBölkeESchererARaffelAGerberPAKröpilPSevere everolimus-induced steatohepatis: a case reportEur J Med Res2013182210.1186/2047-783x-18-22Open DOISearch in Google Scholar
Kuhn B, Jacobsen W, Christians U, Benet LZ, Kollman PA. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem 2001; 44: 2027–34. doi: 10.1021/jm010079yKuhnBJacobsenWChristiansUBenetLZKollmanPAMetabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculationsJ Med Chem20014420273410.1021/jm010079yOpen DOISearch in Google Scholar
Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, Bares R, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC? Diagn Interven Imaging 2014; 95: 289–300. doi: 10.1016/j.diii.2013.07.006Öksüz MÖ, WinterLPfannenbergCReischlGMüssigKBaresRPeptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?Diagn Interven Imaging20149528930010.1016/j.diii.2013.07.006Open DOISearch in Google Scholar
Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of prrt in neuroendocrine tumors. Mol Imag Biol: 2015; 17: 313–8. doi: 10.1007/s11307-014-0795-3KratochwilCStefanovaMMavriopoulouEHolland-LetzTDimitrakopoulou-StraussAAfshar-OromiehASUV of [68Ga]DOTATOC-PET/CT predicts response probability of prrt in neuroendocrine tumorsMol Imag Biol:201517313810.1007/s11307-014-0795-3Open DOISearch in Google Scholar
Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F, et al. (68) Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol 2019; 141: 108–115. doi: 10.1016/j.radonc.2019.09.003SharmaRWangWMYusufSEvansJRamaswamiRWernigF(68) Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumoursRadiother Oncol201914110811510.1016/j.radonc.2019.09.003Open DOISearch in Google Scholar
Kim YI, Yoo C, Oh SJ, Lee SJ, Kang J, Hwang HS, et al. Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Res 2020; 10: 63. doi: 10.1186/s13550-020-00651-zKimYIYooCOhSJLeeSJKangJHwangHSTumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumoursEJNMMI Res2020106310.1186/s13550-020-00651-zOpen DOISearch in Google Scholar
Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, et al. Early changes of the standardized uptake values (SUV(max)) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer. Cancers 2020; 12: 3314 doi: 10.3390/cancers12113314SiricoMBernocchiOSobhaniNGiudiciFCoronaSPVernieriCEarly changes of the standardized uptake values (SUV(max)) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancerCancers202012331410.3390/cancers12113314Open DOISearch in Google Scholar
Michl M, Lehner S, Paprottka PM, Ilhan H, Bartenstein P, Heinemann V, et al. Use of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancer. J Nucl Med 2016; 57: 355–60. doi: 10.2967/jnumed.115.165613MichlMLehnerSPaprottkaPMIlhanHBartensteinPHeinemannVUse of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancerJ Nucl Med2016573556010.2967/jnumed.115.165613Open DOISearch in Google Scholar
Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010; 51: 1349–56. doi: 10.2967/jnumed.110.075002HaugARAuernhammerCJWanglerBSchmidtGPUebleisCGokeB68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumorsJ Nucl Med20105113495610.2967/jnumed.110.075002Open DOISearch in Google Scholar
Opalińska M, Morawiec-Sławek K, Kania-Kuc A, Al Maraih I, Sowa-Staszczak A, Hubalewska-Dydejczyk A. Potential value of pre- and post-therapy [68Ga] Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors. Front Endocrinol 2022; 13: 929391. doi: 10.3389/fendo.2022.929391OpalińskaMMorawiec-SławekKKania-KucAAl MaraihISowa-StaszczakAHubalewska-DydejczykAPotential value of pre- and post-therapy [68Ga] Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumorsFront Endocrinol20221392939110.3389/fendo.2022.929391Open DOISearch in Google Scholar
Ingenerf M, Kiesl S, Karim S, Beyer L, Ilhan H, Rübenthaler J, et al. (68) Ga-DOTATATE PET/CT and MRI with diffusion-weighted imaging (DWI) in short- and long-term assessment of tumor response of neuroendocrine liver metastases (NELM) following transarterial radioembolization (TARE). Cancers 2021; 13: 4321. doi: 10.3390/cancers13174321IngenerfMKieslSKarimSBeyerLIlhanHRübenthalerJ(68) Ga-DOTATATE PET/CT and MRI with diffusion-weighted imaging (DWI) in short- and long-term assessment of tumor response of neuroendocrine liver metastases (NELM) following transarterial radioembolization (TARE)Cancers202113432110.3390/cancers13174321Open DOISearch in Google Scholar
O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology 2016; 280: 576–84. doi: 10.1148/radiol.2016142043OJHLodgeMAWahlRLPractical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0Radiology20162805768410.1148/radiol.2016142043Open DOISearch in Google Scholar
Ilan E, Velikyan I, Sandström M, Sundin A, Lubberink M. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68Ga-DOTATOC and 68Ga-DOTATATE. J Nucl Med 2020; 61: 217–21. doi: 10.2967/jnumed.119.228072IlanEVelikyanISandströmMSundinALubberinkMTumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68Ga-DOTATOC and 68Ga-DOTATATEJ Nucl Med2020612172110.2967/jnumed.119.228072Open DOISearch in Google Scholar